Risk of long-term complications after TFG-β1–guided very-high-dose thoracic radiotherapy
- 15 July 2003
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 56 (4) , 988-995
- https://doi.org/10.1016/s0360-3016(03)00184-6
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose EscalationJournal of Clinical Oncology, 2001
- Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor βInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Circulating IL-6 as a predictor of radiation pneumonitisInternational Journal of Radiation Oncology*Biology*Physics, 2001
- 73.6 Gy and Beyond: Hyperfractionated, Accelerated Radiotherapy for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2001
- Can We Predict Radiation-Induced Changes in Pulmonary Function Based on the Sum of Predicted Regional Dysfunction?Journal of Clinical Oncology, 2001
- Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)International Journal of Radiation Oncology*Biology*Physics, 1999
- Plasma transforming growth factor β1 as a predictor of radiation pneumonitisInternational Journal of Radiation Oncology*Biology*Physics, 1998
- High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early resultsInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Tolerance of normal tissue to therapeutic irradiationPublished by Elsevier ,1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958